Bye Bye Superbugs? New Antibiotic Is Virtually Resistance-Proof

A groundbreaking advancement in antibiotic development might offer a beacon of hope in the fight against antimicrobial resistance. This new class of antibiotics, known as macrolones, employs a dual-pronged strategy that makes it nearly impossible for bacteria to develop resistance.

The innovative design of macrolones enables them to target two critical bacterial processes simultaneously, presenting a formidable challenge for bacterial evolution. Yury Polikanov, an associate professor involved in the research, explains, “By basically hitting two targets at the same concentration, the advantage is that you make it almost impossible for the bacteria to easily come up with a simple genetic defense.”

Macrolones are a synthesis of two well-known antibiotic classes: macrolides and fluoroquinolones. Macrolides, such as erythromycin, work by disrupting bacterial protein synthesis by blocking the ribosome. On the other hand, fluoroquinolones, like ciprofloxacin, target DNA gyrase, an enzyme crucial for DNA replication and repair. The macrolones combine these mechanisms, attacking both the ribosome and DNA gyrase simultaneously.

This dual-target approach has shown remarkable efficacy in preclinical trials. Some macrolones have demonstrated the ability to continue targeting the ribosome even in bacteria that have evolved resistance mutations typically rendering traditional macrolides ineffective. This dual mechanism could be key in combating the rising tide of antibiotic-resistant “superbugs,” which the World Health Organization estimates were responsible for 1.27 million global deaths in 2019 alone.

Alexander Mankin, a senior author of the study, emphasizes the significance of this discovery: “The beauty of this antibiotic is that it kills through two different targets in bacteria. If the antibiotic hits both targets at the same concentration, then the bacteria lose their ability to become resistant via acquisition of random mutations in any of the two targets.”

The promise of macrolones lies not only in their innovative approach but also in their potential to outpace bacterial resistance. As researchers continue to develop and optimize these compounds, they could become a critical tool in averting the so-called “antibiotic apocalypse.”

“The main outcome from all of this work is the understanding of how we need to go forward,” Mankin adds. “And the understanding that we’re giving to chemists is that you need to optimize these macrolones to hit both targets.”

With further development, macrolones could indeed offer a viable solution to one of the most pressing challenges in modern medicine, potentially revolutionizing our approach to treating bacterial infections and providing a robust defense against future resistance crises.